Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. (GENB) is a Healthcare stock tracked by StreetAlpha. It last closed at $13.21 on Nov 2. GENB reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on GENB in the past 90 days. The average target is $30.00, with a high of $30.00 and a low of $30.00, compared with the last close of $13.21.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 8 | HC Wainwright & Co. | Reiterated | Buy | $30 |
| Aug 28 | HC Wainwright & Co. | Target raised | Buy | $16 → $30 |
| Apr 13 | HC Wainwright & Co. | Initiated | Buy | $16 |
Technical Analysis
The stock is 1% below its 20 day and 13% below its 50 day average. Momentum is neutral (RSI 46). The nearest support is the swing low (Jul 17) at $13.20, and the nearest resistance the 20 day average at $13.38.
| RSI (14) | 45.87 | Middle of its range | Neutral |
| MACD | -0.18 | Above its signal line | Bullish |
| Stochastic | 57.1 | Middle of its range | Neutral |
| ADX (14) | 22.2 | Weak trend | |
| Williams %R | -70.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 21.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +5.2% | Change over 10 sessions | Bullish |
| ATR (14) | $1.05 | Typical daily range, 8.0% of price |
| RSI (14) | 47.22 | Middle of its range | Neutral |
| MACD | 0.06 | Below its signal line | Bearish |
| Stochastic | 14.0 | Near the bottom of its range | Oversold |
| ADX (14) | 33.0 | Trending up | |
| Williams %R | -87.3 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -68.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −13.8% | Change over 10 sessions | Bearish |
| ATR (14) | $2.50 | Typical daily range, 18.9% of price |
What happened before
See how GENB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in GENB in the last 90 days.
GENB Institutional Ownership
Hedge fund holdings →- Norges Bank+2.1M sh$35.3M
- BlackRock, Inc.+1.7M sh$28.0M
- Deep Track Capital, LP+1.3M sh$22.5M
- Fmr LLC+1M sh$16.9M
- Vanguard Capital Management LLC+1M sh$16.9M
- ARK Investment Management LLC+786K sh$13.3M
- Jpmorgan Chase & Co−1.5M sh−$26.0M
- Alyeska Investment Group, L.P.−500K sh−$6.3M
- Millennium Management LLC−355K sh−$6.0M
- Braidwell LP−309K sh−$5.2M
- ExodusPoint Capital Management, LP−312K sh−$3.9M
- Goldman Sachs Group Inc−160K sh−$2.7M
- Banque Pictet & Cie SANew+1.8M shOct 16
- CenterBook Partners LPTrimmed−88K shNov 2
- Bank Pictet & Cie (Europe) AGNew+78K shOct 20
- Dynamic Advisor Solutions LLCNew+41K shOct 13
- Sumitomo Mitsui Trust Group, Inc.Added+40K shOct 29
- Tema Etfs LLCNew+20K shOct 16
- Summa Corp.New+17K shOct 29
- PICTET BANK & TRUST LtdNew+17K shOct 21
From SEC Form 13F filings by funds managing over $100 million, as of Jun 30, 2026. Changes compare each fund with its own Q1 2026 filing. Filings come up to 45 days after the quarter ends. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GENB is in one of them and how their past GENB trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GENB in an article yet. Here's the latest on the wider market.